Articles

Could the new EU Medical Devices Regulation put the UK MedTech industry in peril?

There has been much debate in recent years about the difficulty in attracting both private and public funds into the UK biotech industry.  At certain points, it seemed like a disproportionate percentage of the funding that was invested into UK biotech came from the US.  It is likely that there...

Read more

GJE client Lundbeckfonden Emerge invests €2.6 million in SNIPR Biome Limited

On August 25 2017, Lundbeckfonden Emerge announced the completion of a €2.6 million investment in SNIPR Biome Limited. SNIPR Biome is pioneering its proprietary CRISPR technology to revolutionise the treatment of microbial diseases. The constructs developed by SNIPR can subvert elements of the endogenous bacterial CRISPR machinery to targetedly eliminate...

Read more

Unified patent court and the UK: how the complex relationship affects businesses

Patent trolls are a familiar part of the Intellectual Property landscape, although activity in Europe has historically been lower than in the US. With the anticipated arrival of the Unified Patents Court, a single court covering most of the EU market this was expected to change, but the UK’s General...

Read more

Patent risk: understanding the best way to deal with it

If your business is built on technology of any kind, being called out for infringing an existing patent held by another company could easily see your investment in research and development wasted. But while technology is central to most patent disputes, it’s not just technology companies that are at risk...

Read more

Intellectual Property: How To Protect Your Fintech Innovation

Getting to grips with intellectual property (IP) can seem daunting for fledgling FinTech companies just pushing off the starting blocks. However, it’s a step that early-stage businesses, looking to disrupt the market with the latest innovation, cannot afford to overlook. The IP needs of disruptive companies are different from those...

Read more